Yaniel Castro-Torres* and Richard E. Katholi Pages 202 - 211 ( 10 )
Heart Failure (HF) represents a leading cause of morbidity and mortality worldwide. Despite the recent advances in the treatment of this condition, patients´ prognosis remains unfavorable in most cases. Sacubitril/valsartan and ivabradine have been recently approved to improve clinical outcomes in patients with HF with reduced ejection fraction. Drugs under investigation for treating patients with HF encompass many novel mechanisms including vasoactive peptides, blocking inflammatory- mediators, natriuretic peptides, selective non-steroidal mineralocorticoid-receptor antagonists, myocardial β3 adrenoreceptor agonists, inhibiting the cytochrome C/cardiolipin peroxidase complex, neuregulin-1/ErbB signaling and inhibiting late inward sodium current. The aim of this manuscript is to review the main drugs under investigation for the treatment of patients with HF and give perspectives for their implementation into clinical practice.
Heart failure, heart failure reduced ejection fraction, heart failure preserved ejection fraction, heart failure treatment, heart failure management, drugs for HF.
Servicio de Cardiología, Hospital Universitario Celestino Hernández Robau, Santa Clara, Villa Clara, Department of Pharmacology, Southern Illinois School of Medicine, Springfield, IL 62702